Dementia with Lewy bodies

McKeith, Ian G.; Mintzer, Jacobo; Aarsland, Dag; Burn, David J.; Chiu, Helen Fung Kum; Cohen‐Mansfield, Jiska; Dickson, Dennis W.; Dubois, Bruno; Duda, John E.; Feldman, Howard; Gauthier, Serge; Halliday, Glenda M.; Lawlor, Brian; Lippa, Carol F.; López, Oscar L.; Machado, João Carlos; O’Brien, John T.; Playfer, Jeremy

doi:10.1016/s1474-4422(03)00619-7

Cited by 617 publications

(442 citation statements)

References 95 publications

Supporting

Mentioning

412

Contrasting

Unclassified

Order By: Relevance

“…42 It shares clinical and pathologic characteristics of other dementias that may occur during the course of Parkinson's disease and other neurologic conditions. 43,44 Pathologically, DLB is characterized by abnormal aggregation of the synaptic proteinsynuclein as 'Lewy bodies' in neurons associated with brain atrophy, which is not as robust as in AD. 45 Cerebrovascular dysfunction and neuroinflammation in dementia with Lewy bodies.…”

Section: Dementia With Lewy Bodiesmentioning

confidence: 99%

The neuropathology and cerebrovascular mechanisms of dementia

Raz

Knoefel

Bhaskar

2015

J Cereb Blood Flow Metab

331

284

View full text Add to dashboard Cite

The prevalence of dementia is increasing in our aging population at an alarming rate. Because of the heterogeneity of clinical presentation and complexity of disease neuropathology, dementia classifications remain controversial. Recently, the National Plan to address Alzheimer's Disease prioritized Alzheimer's disease-related dementias to include: Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, and mixed dementias. While each of these dementing conditions has their unique pathologic signature, one common etiology shared among all these conditions is cerebrovascular dysfunction at some point during the disease process. The goal of this comprehensive review is to summarize the current findings in the field and address the important contributions of cerebrovascular, physiologic, and cellular alterations to cognitive impairment in these human dementias. Specifically, evidence will be presented in support of small-vessel disease as an underlying neuropathologic hallmark of various dementias, while controversial findings will also be highlighted. Finally, the molecular mechanisms shared among all dementia types including hypoxia, oxidative stress, mitochondrial bioenergetics, neuroinflammation, neurodegeneration, and bloodbrain barrier permeability responsible for disease etiology and progression will be discussed.

show abstract

Section: Dementia With Lewy Bodiesmentioning

confidence: 99%

The neuropathology and cerebrovascular mechanisms of dementia

Raz

Knoefel

Bhaskar

2015

J Cereb Blood Flow Metab

331

284

View full text Add to dashboard Cite

show abstract

“…Dementia with Lewy Bodies (DLB) is likely the second most common form of neurodegenerative dementia with a prevalence between 3% and 26% of all demented cases older than 65 years [9,20]. The clinical picture of DLB constitutes of fluctuations in cognitive performance and consciousness, as well as Parkinsonism, visual hallucinations, falls and severe sensitivity to neuroleptic agents [9]. Accurate diagnosis of the different dementias as well as identification of specific biomarkers has important implications for current treatments and clinical trials for novel therapies.…”

Section: Introductionmentioning

confidence: 99%

Reduced CSF CART in dementia with Lewy bodies

Schultz

Wiehager

Nilsson

et al. 2009

Neuroscience Letters

View full text Add to dashboard Cite

Dementia with Lewy bodies (DLB) is the second most common form of neurodegenerative dementia after Alzheimer's disease (AD). The underlying neurobiological mechanism of DLB is not fully understood and no generally accepted biomarkers are yet available for the diagnosis of DLB. In a recent MRI study, DLB patients displayed hypothalamic atrophy whereas this region was not affected in AD patients. Cocaine and amphetamine regulated transcript (CART) is a neuropeptide expressed selectively in neurons in the hypothalamus.Here, we found that CSF CART levels were significantly reduced by 30% in DLB patients (n=12) compared to controls (n=12) as well as to AD patients (n=14) using radioimmunoassay. Our preliminary results suggest that reduced CSF CART is a sign of hypothalamic dysfunction in DLB and that it may serve as a biomarker for this patient group.

show abstract

“…Fluctuating symptoms are not so uncommon in demented patients, but are more characteristic of dementia with Lewy bodies 5 while Mrs. B has a typical presentation of Alzheimer's disease. Generally, these patients present mostly aggravations or delirium but rarely recovery.…”

Section: Discussionmentioning

confidence: 99%

A transient awakening of a patient with Alzheimer's disease that questions our practice

Bloch

2016

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageImprovements are not usually described in the natural history of degenerative dementia. It seems possible to find the normal workings of impaired learning and lost long‐term memories that appeared to be permanently altered after severe neurodegeneration and synaptic loss. The activation of these programs seems to represent the basis of the dysfunction, rather than the program itself.

show abstract

Dementia with Lewy bodies

Cited by 617 publications

References 95 publications

The neuropathology and cerebrovascular mechanisms of dementia

The neuropathology and cerebrovascular mechanisms of dementia

Reduced CSF CART in dementia with Lewy bodies

A transient awakening of a patient with Alzheimer's disease that questions our practice

Contact Info

Product

Resources

About